Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancers Recruiting

2023-507774-41-00 Advanced cancer histologies for which immune checkpoint 2024-05-29
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting

2023-508808-38-00 Solid tumors 2024-05-29
A study of ASP3082 in adults with advanced solid tumors Recruiting

2022-501590-39-00 Solid Tumor 2024-05-22
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD… Recruiting

2023-506888-34-00 Advanced or metastatic solid tumors including hormone r 2024-05-22
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma Recruiting

2023-507213-97-00 Relapsed/refractory B-cell aggressive lymphoma 2024-05-09
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with re… Recruiting

2023-508420-36-00 Relapsed/refractory B-cell Acute Lymphoblastic Leukemia 2024-04-23
A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people… Recruiting

2022-502576-23-00 Platinum-resistant recurrent (PRR) ovarian cancer, Plat 2024-04-17
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting

2022-501725-21-00 Neuroblastoma 2024-04-12
A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors Recruiting

2023-505358-16-00 Advanced Solid Tumors 2024-04-11
Phase 1b Study of ION356 to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics in Patients with Pelizaeus-Merzbacher Disease Recruiting

2022-502432-39-00 Pelizaeus-Merzbacher Disease 2024-04-10
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Recruiting

2023-508058-24-01 LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLOREC 2024-04-05
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults. Recruiting

2023-508305-24-00 Movement disorders 2024-03-29
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in C… Recruiting

2023-507611-35-00 mild to moderate asthma 2024-03-01
A Phase I Study of VVD-133214 Alone and in Combination in Participants with Advanced Solid Tumors Recruiting

2023-503170-20-01 Advanced solid tumors 2024-02-26
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with r… Recruiting

2022-502831-20-00 Male and female adult patients with relapsed Multiple M 2024-02-15
Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting

2023-506604-18-00 Triple negative breast cancer 2024-02-14
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with u… Recruiting

2023-507547-11-00 Ulcerative colitis 2024-02-09
A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting

2022-502514-86-00 Myeloproliferative Neoplasms 2024-02-07
First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations. Recruiting

2023-509158-68-00 Parkinson’s disease 2024-01-25
A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1… Recruiting

2023-508543-42-00 Chronic heart failure 2024-01-22
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in pat… Recruiting

2022-503084-15-00 Progressive metastatic solid cancer after failure of es 2024-01-12
DS-1103a Combination Therapy First-in-human (FIH) Study Recruiting

2023-503965-48-00 Advanced (unresectable or metastatic) human epidermal g 2024-01-11
Trial to evaluate CAR-T NKG2D CAR cell infusions in patients with advanced sarcoma Recruiting

2024-513514-35-00 Sarcoma 2024-01-10
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients Recruiting

2023-507075-22-00 A Phase 1, Randomized, Double-Blind, Placebo-Controlled 2024-01-05